POS0134 LEARNING FROM LONGITUDINAL DATA IN CHILDHOOD ONSET SYSTEMIC LUPUS ERYTHEMATOSUS: WHICH BIOMARKERS HAVE PREDICTIVE VALUE FOR ENDOTHELIAL INVOLVEMENT?
BackgroundIn (childhood-onset) systemic lupus erythematosus ((c)SLE), patients have an increased risk of developing premature atherosclerosis [1]. The pathophysiological mechanisms for this atherosclerosis are not completely understood. Besides traditional risk factors, the endothelium plays a major...
Saved in:
Published in | Annals of the rheumatic diseases Vol. 82; no. Suppl 1; pp. 286 - 287 |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
London
BMJ Publishing Group LTD
01.06.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | BackgroundIn (childhood-onset) systemic lupus erythematosus ((c)SLE), patients have an increased risk of developing premature atherosclerosis [1]. The pathophysiological mechanisms for this atherosclerosis are not completely understood. Besides traditional risk factors, the endothelium plays a major role [2]. Dysregulated endothelial cell markers and proteins involved in endothelial function in SLE are not always correlated to disease activity, which could mean that the endothelium stays in a dysregulated state in SLE, even with low disease activity (Bergkamp et al., submitted). However, previous studies were mostly cross-sectional and only performed in adult SLE, while childhood-onset SLE (cSLE) has a longer and more severe course [3,4].ObjectivesTo measure the serum levels of a panel of SLE-associated markers involved in endothelial cell (EC) function, in longitudinal samples of cSLE patients (active vs. low SLE disease activity index (SLEDAI)) and to compare them with healthy controls and assess their correlation with disease activity.MethodsBlood samples and patient characteristics were collected from a multicentre longitudinal cSLE study and compared with age- and sex-matched healthy controls (HC). Disease activity was evaluated by SLEDAI-2K, with cut-offs for active (>4) versus low (≤4) activity. Serum levels of CXCL12 (SDF-1), TWEAK, VEGF, CXCL10 (IP-10), ADAMTS13, Angiopoietin-2, Pentraxin-3, E-Selectin, Thrombomodulin, P-selectin, CCL2 (MCP-1), VCAM-1, ICAM-1, vWF-A2 and Gas6 were measured in two cSLE samples (t=1 and t=2) and in HC (1 sample). Patient groups and healthy controls were compared by t-tests and ANOVA, with significance for p < 0.05. Correlations between marker serum levels and SLEDAI were calculated with Pearson correlation.ResultsThis study included 47 cSLE patients (30 treatment-naïve) and 42 healthy controls. Mean age at diagnosis in cSLE was 14 (± 2.33) years. Median SLEDAI at t=1 was 12 (IQR 6-18). Median SLEDAI t=2 was 2.5 (IQR 2-6). Time between two blood samples was 14.5 months (IQR 9-24 months). Median disease duration at t=1 was 0 months (IQR 0-18 months) and at t=2 16.5 months (IQR 10-53 months). Ethnic background in patients was 42.6% Caucasian, 36.2% African/Afro-Caribbean, 8.5% North-African/Middle East, 4.3% Asian and 8.5% mixed/other ethnic background. At t=1, serum levels of CXCL10 (p=0.01), Thrombomodulin (p=0.03) and VCAM-1 (p=0.01) were higher in the group with active cSLE compared to those with low disease activity. Serum levels for CXCL10, Pentraxin-3, Thrombomodulin, P-selectin, vWF-A2 and Gas6 correlated with SLEDAI score. Angiopoietin-2 and VCAM-1 were upregulated in cSLE patients versus healthy controls (both p<0.001),but not related to disease activity (figure 1A). Levels of CXCL10, Angiopoietin-2, Pentraxin-3, E-Selectin, CCL2, VCAM-1 and vWF-A2 decreased over time, while serum levels of TWEAK increased over time (all p<0.05) (figure 1B).ConclusionAt different time points, serum levels of Angiopoietin-2 (t=1), VCAM-1 (t=1) and TWEAK (t=2) were increased in cSLE patients, irrespective of disease activity. These markers represent activation of ECs with vascular inflammation, EC activation and a pro-angiogenic state. The endothelium in cSLE seems to stay in an active state, even in low disease activity (SLEDAI≤4). Our findings suggest that some EC markers might be useful as biomarkers for predicting the ongoing risk for endothelial dysfunction in cSLE.References[1]Ardoin SP, Schanberg LE, et al. Laboratory markers of cardiovascular risk in pSLE: the APPLE baseline cohort. Lupus. 2010 PMID: 20861207[2]Westerweel PE, Luyten RK, et al. Premature atherosclerotic cardiovascular disease in SLE. Arthritis Rheum. 2007 May; 1384-96. PMID: 17469095[3]Brunner HI, Silverman ED et al. Difference in disease features between cSLE and aSLE. Arthr and rheum. 2008;58(2):556-62[4]Groot N, Shaikhani D, R, et al. Long-Term Clinical Outcomes in a Cohort of Adults With cSLE. Arthritis Rheumatol. 2019;71(2):290-301Acknowledgements:NIL.Disclosure of InterestsNone Declared. |
---|---|
AbstractList | BackgroundIn (childhood-onset) systemic lupus erythematosus ((c)SLE), patients have an increased risk of developing premature atherosclerosis [1]. The pathophysiological mechanisms for this atherosclerosis are not completely understood. Besides traditional risk factors, the endothelium plays a major role [2]. Dysregulated endothelial cell markers and proteins involved in endothelial function in SLE are not always correlated to disease activity, which could mean that the endothelium stays in a dysregulated state in SLE, even with low disease activity (Bergkamp et al., submitted). However, previous studies were mostly cross-sectional and only performed in adult SLE, while childhood-onset SLE (cSLE) has a longer and more severe course [3,4].ObjectivesTo measure the serum levels of a panel of SLE-associated markers involved in endothelial cell (EC) function, in longitudinal samples of cSLE patients (active vs. low SLE disease activity index (SLEDAI)) and to compare them with healthy controls and assess their correlation with disease activity.MethodsBlood samples and patient characteristics were collected from a multicentre longitudinal cSLE study and compared with age- and sex-matched healthy controls (HC). Disease activity was evaluated by SLEDAI-2K, with cut-offs for active (>4) versus low (≤4) activity. Serum levels of CXCL12 (SDF-1), TWEAK, VEGF, CXCL10 (IP-10), ADAMTS13, Angiopoietin-2, Pentraxin-3, E-Selectin, Thrombomodulin, P-selectin, CCL2 (MCP-1), VCAM-1, ICAM-1, vWF-A2 and Gas6 were measured in two cSLE samples (t=1 and t=2) and in HC (1 sample). Patient groups and healthy controls were compared by t-tests and ANOVA, with significance for p < 0.05. Correlations between marker serum levels and SLEDAI were calculated with Pearson correlation.ResultsThis study included 47 cSLE patients (30 treatment-naïve) and 42 healthy controls. Mean age at diagnosis in cSLE was 14 (± 2.33) years. Median SLEDAI at t=1 was 12 (IQR 6-18). Median SLEDAI t=2 was 2.5 (IQR 2-6). Time between two blood samples was 14.5 months (IQR 9-24 months). Median disease duration at t=1 was 0 months (IQR 0-18 months) and at t=2 16.5 months (IQR 10-53 months). Ethnic background in patients was 42.6% Caucasian, 36.2% African/Afro-Caribbean, 8.5% North-African/Middle East, 4.3% Asian and 8.5% mixed/other ethnic background. At t=1, serum levels of CXCL10 (p=0.01), Thrombomodulin (p=0.03) and VCAM-1 (p=0.01) were higher in the group with active cSLE compared to those with low disease activity. Serum levels for CXCL10, Pentraxin-3, Thrombomodulin, P-selectin, vWF-A2 and Gas6 correlated with SLEDAI score. Angiopoietin-2 and VCAM-1 were upregulated in cSLE patients versus healthy controls (both p<0.001),but not related to disease activity (figure 1A). Levels of CXCL10, Angiopoietin-2, Pentraxin-3, E-Selectin, CCL2, VCAM-1 and vWF-A2 decreased over time, while serum levels of TWEAK increased over time (all p<0.05) (figure 1B).ConclusionAt different time points, serum levels of Angiopoietin-2 (t=1), VCAM-1 (t=1) and TWEAK (t=2) were increased in cSLE patients, irrespective of disease activity. These markers represent activation of ECs with vascular inflammation, EC activation and a pro-angiogenic state. The endothelium in cSLE seems to stay in an active state, even in low disease activity (SLEDAI≤4). Our findings suggest that some EC markers might be useful as biomarkers for predicting the ongoing risk for endothelial dysfunction in cSLE.References[1]Ardoin SP, Schanberg LE, et al. Laboratory markers of cardiovascular risk in pSLE: the APPLE baseline cohort. Lupus. 2010 PMID: 20861207[2]Westerweel PE, Luyten RK, et al. Premature atherosclerotic cardiovascular disease in SLE. Arthritis Rheum. 2007 May; 1384-96. PMID: 17469095[3]Brunner HI, Silverman ED et al. Difference in disease features between cSLE and aSLE. Arthr and rheum. 2008;58(2):556-62[4]Groot N, Shaikhani D, R, et al. Long-Term Clinical Outcomes in a Cohort of Adults With cSLE. Arthritis Rheumatol. 2019;71(2):290-301Acknowledgements:NIL.Disclosure of InterestsNone Declared. |
Author | Kuijpers, T J M Van den Berg Wahadat, M J Smit, M D Schonenberg-Meinema Bergkamp, S Kamphuis, S A Nassar-Sheikh Rashid Tas, S Gruppen, M Bergkamp, N |
Author_xml | – sequence: 1 givenname: S surname: Bergkamp fullname: Bergkamp, S – sequence: 2 givenname: N surname: Bergkamp fullname: Bergkamp, N – sequence: 3 givenname: M surname: Wahadat middlename: J fullname: Wahadat, M J – sequence: 4 givenname: M surname: Gruppen fullname: Gruppen, M – sequence: 5 fullname: A Nassar-Sheikh Rashid – sequence: 6 givenname: T surname: Kuijpers fullname: Kuijpers, T – sequence: 7 givenname: S surname: Tas fullname: Tas, S – sequence: 8 givenname: M surname: Smit fullname: Smit, M – sequence: 9 givenname: S surname: Kamphuis fullname: Kamphuis, S – sequence: 10 fullname: J M Van den Berg – sequence: 11 fullname: D Schonenberg-Meinema |
BookMark | eNqNTT1OwzAYtVCRaIE7fFLnFDtJ08CCTPK1tnDsynaCOlWVCIKqpJCQnYVrcDhOQgYOwPT-9SZk1BybmpApozPGouRq1zTtc92_Pr50QUjDKKj7w66dxSxmJ2TM4iQd7ISOyJhSGgXxdbI4I5Ou2w-Spiwdk--1cZRF8c_nl0JutdQrWFpTgDJ6JX2ZS80V5NxzkBoyIVUujMnBaIce3MZ5LGQGqlyXDtBuvMCCe-NKdwMPQmYC7qQpuL1H60DwCmFtMZeZlwOtuCoRlsYC6twMUyWHM6kroyosUPvbC3L6tDt09eUfnpPpEn0mgrf2-N7X3cd2f-zbZoi2YRrOw0W0YPPof61fKLtbWg |
ContentType | Journal Article |
Copyright | 2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. |
Copyright_xml | – notice: 2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. |
DBID | K9. |
DOI | 10.1136/annrheumdis-2023-eular.4141 |
DatabaseName | ProQuest Health & Medical Complete (Alumni) |
DatabaseTitle | ProQuest Health & Medical Complete (Alumni) |
DatabaseTitleList | ProQuest Health & Medical Complete (Alumni) |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1468-2060 |
EndPage | 287 |
GroupedDBID | --- .55 .VT 0R~ 23M 39C 4.4 40O 53G 5GY 5RE 5VS 6J9 7X7 7~S 88E 88I 8AF 8FE 8FH 8FI 8FJ AAHLL AAOJX AAWJN AAWTL ABAAH ABJNI ABKDF ABMQD ABOCM ABTFR ABUWG ABVAJ ACGFO ACGFS ACGOD ACGTL ACHTP ACMFJ ACOFX ACPRK ACTZY ADBBV ADFRT ADUGQ AEKJL AENEX AFKRA AFWFF AHMBA AHNKE AHQMW AJYBZ AKKEP ALIPV ALMA_UNASSIGNED_HOLDINGS AZQEC BBNVY BENPR BHPHI BKNYI BLJBA BOMFT BPHCQ BTHHO C45 CCPQU CS3 CXRWF DIK DWQXO E3Z EBS F5P FYUFA GNUQQ H13 HAJ HCIFZ HMCUK HZ~ IAO IOF K9- K9. L7B LK8 M0R M1P M2P M7P N9A NXWIF O9- OVD P2P PQQKQ PROAC PSQYO RHF RHI RMJ RV8 RWL RXW TAE TEORI TR2 UAW UKHRP UYXKK V24 VVN WH7 X6Y X7M YFH YOC YQY |
ID | FETCH-proquest_journals_28252737153 |
ISSN | 0003-4967 |
IngestDate | Thu Oct 10 22:22:30 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | Suppl 1 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-proquest_journals_28252737153 |
PQID | 2825273715 |
PQPubID | 2041045 |
ParticipantIDs | proquest_journals_2825273715 |
PublicationCentury | 2000 |
PublicationDate | 20230601 |
PublicationDateYYYYMMDD | 2023-06-01 |
PublicationDate_xml | – month: 06 year: 2023 text: 20230601 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | London |
PublicationPlace_xml | – name: London |
PublicationTitle | Annals of the rheumatic diseases |
PublicationYear | 2023 |
Publisher | BMJ Publishing Group LTD |
Publisher_xml | – name: BMJ Publishing Group LTD |
SSID | ssj0000818 |
Score | 4.9342694 |
Snippet | BackgroundIn (childhood-onset) systemic lupus erythematosus ((c)SLE), patients have an increased risk of developing premature atherosclerosis [1]. The... |
SourceID | proquest |
SourceType | Aggregation Database |
StartPage | 286 |
SubjectTerms | Angiogenesis Angiopoietin Arteriosclerosis Arthritis Atherosclerosis Biomarkers Cardiovascular diseases Children CXCL10 protein CXCL12 protein E-selectin Endothelial cells Endothelium Intercellular adhesion molecule 1 IP-10 protein Lupus Monocyte chemoattractant protein 1 P-selectin Patients Pentraxins Risk factors SDF-1 protein Serum levels Systemic lupus erythematosus Thrombomodulin Vascular cell adhesion molecule 1 Vascular endothelial growth factor |
Title | POS0134 LEARNING FROM LONGITUDINAL DATA IN CHILDHOOD ONSET SYSTEMIC LUPUS ERYTHEMATOSUS: WHICH BIOMARKERS HAVE PREDICTIVE VALUE FOR ENDOTHELIAL INVOLVEMENT? |
URI | https://www.proquest.com/docview/2825273715 |
Volume | 82 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ1Jb5tAFIBHjiNFvVRd1TRpNFJ6Q7g1i4FeKmLGgRQYi8VxThYDpJGquJZrX3rqpX-jP679I50FDG4iq-0F4bHMAO_z4_HmLQC81kxiqdcDRS5IXsiaRnI5U3RTJlpRDKy8zC2TJQoH4cBNtYupPu10frWiltYr0su_3ptX8j9SpWNUrixL9h8kuzkoHaD7VL50SyVMt38l4zGOqW2lVQELpu4jOwqZ-2kU4UDycXjuMYOPBfc4dmJLXsicbL7jYuxIOIxRIsVXccJF4afjNJZQdJW4KLATHKcx8xZcut7Qlc48HNjRB5aO4NoTxOTmeMPEo7sT20-RRN8lJRQ6mP7Y9-h0XjjB_oR3CvgjdLCp2MyDG2_KtSgaW60UNV77cvnxU3a72HLPtgc3a0iX2U1WZCLspFnlOl-uFwuhU4O2a0NRmxAs4b8LLu4441otRIQ-V2XNEg09eqVQ4SyXTHkruhTUOt5UWizzfqlSv62263Lc1Sfj_oeLWlVV5veG3haZn3TJ4oV7Wl8U8Nou6R3i2Sj1_VmCpske2FcMS9e7YP8MheOoMRjMvlk3dmQXcwBOq-ne7JjsjvHALaLkEXhYvcpAW3D5GHTK-RNwEFTBGk_BjwrPn9--12BCBiZsgwkZmNAL4QZMyMGENZiQgwm3wHwHOZawwRIyLGGDJeRYQoolbGEJW1i-fwZORygZunJ9fbPqP_dlxjKtqcFt0Of0c9Cdf56XLwDUCVGpGWoZCjG0PO-b5rVpGVlWEIslGZaH4HjXkV7u_voIPGjYPAbd1XJdvqKG6IqcgD1japxU4vwN3PB73Q |
link.rule.ids | 315,786,790,27955,27956,31752,33777 |
linkProvider | ProQuest |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=POS0134%E2%80%85LEARNING+FROM+LONGITUDINAL+DATA+IN+CHILDHOOD+ONSET+SYSTEMIC+LUPUS+ERYTHEMATOSUS%3A+WHICH+BIOMARKERS+HAVE+PREDICTIVE+VALUE+FOR+ENDOTHELIAL+INVOLVEMENT%3F&rft.jtitle=Annals+of+the+rheumatic+diseases&rft.au=Bergkamp%2C+S&rft.au=Bergkamp%2C+N&rft.au=Wahadat%2C+M+J&rft.au=Gruppen%2C+M&rft.date=2023-06-01&rft.pub=BMJ+Publishing+Group+LTD&rft.issn=0003-4967&rft.eissn=1468-2060&rft.volume=82&rft.issue=Suppl+1&rft.spage=286&rft.epage=287&rft_id=info:doi/10.1136%2Fannrheumdis-2023-eular.4141&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0003-4967&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0003-4967&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0003-4967&client=summon |